PE20151655A1 - Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizado - Google Patents
Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizadoInfo
- Publication number
- PE20151655A1 PE20151655A1 PE2015001910A PE2015001910A PE20151655A1 PE 20151655 A1 PE20151655 A1 PE 20151655A1 PE 2015001910 A PE2015001910 A PE 2015001910A PE 2015001910 A PE2015001910 A PE 2015001910A PE 20151655 A1 PE20151655 A1 PE 20151655A1
- Authority
- PE
- Peru
- Prior art keywords
- agglomerates
- breathable
- micronized drug
- carrier particles
- present
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000000843 powder Substances 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151655A1 true PE20151655A1 (es) | 2015-11-26 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001910A PE20151655A1 (es) | 2013-03-14 | 2014-03-13 | Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizado |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (enExample) |
| EP (1) | EP2968570A1 (enExample) |
| JP (1) | JP6374414B2 (enExample) |
| KR (1) | KR20150129716A (enExample) |
| CN (1) | CN105188757B (enExample) |
| AU (2) | AU2014229265A1 (enExample) |
| BR (1) | BR112015021814A2 (enExample) |
| CA (1) | CA2905615A1 (enExample) |
| CL (1) | CL2015002632A1 (enExample) |
| EA (1) | EA201591729A1 (enExample) |
| GT (1) | GT201500295A (enExample) |
| HK (1) | HK1212616A1 (enExample) |
| IL (1) | IL240963A (enExample) |
| MA (1) | MA38397A1 (enExample) |
| MX (1) | MX2015012814A (enExample) |
| PE (1) | PE20151655A1 (enExample) |
| PH (1) | PH12015501882A1 (enExample) |
| SA (1) | SA515361055B1 (enExample) |
| SG (1) | SG11201506397QA (enExample) |
| TN (1) | TN2015000395A1 (enExample) |
| WO (1) | WO2014141135A1 (enExample) |
| ZA (1) | ZA201505768B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| BR112015018121A2 (pt) * | 2013-01-31 | 2017-07-18 | Prosonix Ltd | composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| WO2015145353A1 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| WO2020247376A1 (en) * | 2019-06-03 | 2020-12-10 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| WO2021030307A1 (en) * | 2019-08-15 | 2021-02-18 | Abbott Laboratories | Nutritional powder manufacturing process using micronization, and powder composition |
| CN115916173A (zh) * | 2020-04-13 | 2023-04-04 | 巴塞尔大学医院 | Lsd剂量鉴定 |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| TW202237102A (zh) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 用於肺部遞送的藥物組合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| US20230064429A1 (en) | 2021-08-19 | 2023-03-02 | Mind Medicine, Inc. | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| CN116785246B (zh) * | 2022-03-17 | 2026-06-12 | 上海惠永药物研究有限公司 | 一种药物微球及含其的气雾剂 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| WO2025256638A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海济昀生物科技有限公司 | 一种混悬型三联吸入气雾剂组合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| NZ243314A (en) | 1991-06-26 | 1994-07-26 | Schering Corp | Powder dispenser; single metered dose rotated to dispensing conduit |
| JP2924924B2 (ja) | 1992-12-18 | 1999-07-26 | シェリング・コーポレーション | 粉末薬物のための吸入器 |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| ATE387925T1 (de) | 1994-09-21 | 2008-03-15 | Nektar Therapeutics | Vorrichtung und verfahren zum dispergieren von trockenen pulvermedikamenten |
| CN1213974A (zh) | 1996-01-03 | 1999-04-14 | 葛兰素集团有限公司 | 吸入器具 |
| DK0883415T3 (da) | 1996-02-21 | 2002-08-19 | Schering Corp | Inhalator til pulverformigt medikament |
| SI0937041T1 (en) | 1996-11-11 | 2003-10-31 | Christian R. Noe | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| CN1150895C (zh) | 1998-11-13 | 2004-05-26 | 杰格研究股份公司 | 用于吸入给药的干粉 |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| PT1181069E (pt) | 1999-05-28 | 2006-11-30 | Nektar Therapeutics | Dispositivo e método para a administração de uma dose calibrada de medicamento em aerosol |
| US20010029947A1 (en) | 1999-12-17 | 2001-10-18 | Steve Paboojian | Receptacles to facilitate the extraction of powders |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| JP2006511617A (ja) | 2002-12-13 | 2006-04-06 | アダーギット | 製薬用多孔質粒子 |
| AU2004229446B2 (en) | 2003-04-09 | 2010-02-25 | Bgp Products Operations Gmbh | Aerosolization apparatus with air inlet shield |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| PL1718353T3 (pl) | 2004-02-24 | 2020-06-01 | Microdose Therapeutx, Inc. | Urządzenie do dostarczania leku na bazie strugi syntetycznej |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| US8198450B2 (en) | 2006-06-30 | 2012-06-12 | Novartis Ag | Quinolinone derivatives and their pharmaceutical compositions |
| EP2668970B1 (en) | 2006-10-25 | 2016-07-06 | Novartis AG | Powder dispersion apparatus |
| US8834930B2 (en) | 2008-05-15 | 2014-09-16 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
| KR101290893B1 (ko) | 2009-04-09 | 2013-07-29 | 노파르티스 아게 | 피롤리디늄 염의 제조 방법 |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| WO2011120779A1 (en) | 2010-04-01 | 2011-10-06 | Chiesi Farmaceutici S.P.A. | Process for preparing carrier particles for dry powders for inhalation |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en not_active Ceased
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Ceased
- 2014-03-13 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591729A1 (ru) | 2016-05-31 |
| EP2968570A1 (en) | 2016-01-20 |
| US9744178B2 (en) | 2017-08-29 |
| AU2017203258A1 (en) | 2017-06-08 |
| SA515361055B1 (ar) | 2016-11-13 |
| AU2017203258B2 (en) | 2019-06-20 |
| MX2015012814A (es) | 2016-02-03 |
| AU2014229265A1 (en) | 2015-09-03 |
| JP6374414B2 (ja) | 2018-08-15 |
| ZA201505768B (en) | 2017-03-29 |
| IL240963A (en) | 2017-05-29 |
| PH12015501882A1 (en) | 2015-12-07 |
| BR112015021814A2 (pt) | 2017-07-18 |
| GT201500295A (es) | 2017-09-28 |
| US20160354388A1 (en) | 2016-12-08 |
| CN105188757B (zh) | 2019-04-30 |
| CN105188757A (zh) | 2015-12-23 |
| US20140302147A1 (en) | 2014-10-09 |
| SG11201506397QA (en) | 2015-09-29 |
| CL2015002632A1 (es) | 2016-03-28 |
| US9452139B2 (en) | 2016-09-27 |
| WO2014141135A1 (en) | 2014-09-18 |
| IL240963A0 (en) | 2015-11-30 |
| CA2905615A1 (en) | 2014-09-18 |
| TN2015000395A1 (en) | 2017-01-03 |
| JP2016512494A (ja) | 2016-04-28 |
| HK1212616A1 (zh) | 2016-06-17 |
| KR20150129716A (ko) | 2015-11-20 |
| MA38397A1 (fr) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002632A1 (es) | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado | |
| CL2016000735A1 (es) | Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc. | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| BR112018008880A8 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| NI201600037A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso. | |
| HUE053957T2 (hu) | Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra | |
| MX2018005384A (es) | Composiciones y metodos para fabricar microparticulas de proteina. | |
| PE20151979A1 (es) | Compuestos quimicos | |
| BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
| AR098333A1 (es) | Una composición en forma de polvo | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 | |
| CL2016001843A1 (es) | Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero. | |
| CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
| EA201591988A1 (ru) | Гетероциклическое ацетамидное соединение | |
| CR20160432A (es) | Inhibidores de las vías de señalización de wnt | |
| CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. | |
| MX373624B (es) | Formulación de ceritinib. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |